Daiichi Sankyo has emerged victorious in appeals court, flipping a prior multimillion-dollar patent verdict on its head and ...
In the January 2025 presentation, Jazz Pharmaceuticals expects zanidatamab to potentially receive approval and be launched as ...
The Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab deruxtecan or Dato-DXd) for adult patients with locally advanced or metastatic ...
The first patient has been dosed in the randomization phase of the DESTINY-Ovarian01 phase 3 trial evaluating Enhertu in combination with ...
AstraZeneca and its partner Daiichi Sankyo have obtained the Food and Drug Administration’s green light for Datroway to treat an advanced form of non-small cell lung cancer in adults who had received ...
(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Tuesday that the U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan or Dato-DXd), co-developed with ...
More recently, the FDA posted two two letters: one backdated for September 9, regarding GSK’s HIV medication Apretude and one backdated for November 24 for Daiichi Sankyo’s tenosynovial giant cell ...
The federal appeals court has now reversed the 2022 verdict upholding the '039 patent, thereby vacating the Texas court's ...
AstraZeneca and Daiichi Sankyo's Datroway drug has been approved in the U.S. to treat adult patients with non-small cell lung cancer. British pharmaceutical company AstraZeneca said Tuesday that the ...
Daiichi Sankyo, Inc. today announced a co-commercialization agreement with AstraZeneca for MOVANTIK™ (naloxegol) in the US, in line with the Daiichi Sankyo strategy to expand its US portfolio through ...
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo have received priority review from the FDA for their supplemental marketing application for Enhertu in combination with pertuzumab, marketed by Roche (OTCQX ...
Clinical Trials Arena on MSN
Daiichi Sankyo announces first patient dosed in phase III trial of Enhertu
Daiichi Sankyo has announced the dosing of first patient in the DESTINY-Ovarian01 Phase III trial’s randomisation phase, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback